Skip to main content
. Author manuscript; available in PMC: 2017 Jun 15.
Published in final edited form as: J Immunol. 2016 May 13;196(12):5112–5120. doi: 10.4049/jimmunol.1502153

Figure 6. PGE2 is required for enhanced SOCS3 secretion during LPS treatment in vivo.

Figure 6

(A) PGE2 levels in BALF 24 h after oropharyngeal administration of LPS (2.5 μg/mouse) to wild type mice, as determined by ELISA. (B) SOCS3 levels in BALF 24 h after oropharyngeal administration of LPS in wild type mice pretreated or not with 1.5 mg/kg indomethacin. (C) SOCS3 levels in BALF 24 h after oropharyngeal administration of LPS to mPGEs-1 KO mice. Data are expressed as mean ± SEM, n= 5 mice per group, *= p<0.05.